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Infectious Disease

Epidemiology of Bloodstream Infections in a
Multicenter Retrospective Cohort of Liver
Transplant Recipients
Carlos A.Q. Santos, MD,1 Richard S. Hotchkiss, MD,2 William C. Chapman, MD,3 Margaret A. Olsen, PhD, MPH1,4

Background. Although some studies have examined the epidemiology of bloodstream infections after liver transplantation, they
were based in single centers and did not identify bloodstream infections treated in other hospitals. Methods. We retrospectively
examined a cohort of 7912 adult liver transplant recipients from 24 transplant centers using 2004 to 2012 International Classification of Diseases, Ninth Revision, Clinical Modification billing data from 3 State Inpatient Databases, and identified bloodstream
infections, inpatient death, and cumulative 1-year hospital costs. Multilevel Cox regression analyses were used to determine
factors associated with bloodstream infections and death. Results. Bloodstream infections were identified in 29% (n = 2326)
of liver transplant recipients, with a range of 19% to 40% across transplant centers. Only 63% of bloodstream infections occurring
more than 100 days posttransplant were identified at the original transplant center. Bloodstream infections were associated
with posttransplant laparotomy (adjusted hazard ratio [aHR], 1.52), prior liver transplant (aHR, 1.42), increasing age (aHR, 1.07/
decade), and some comorbidities. Death was associated with bloodstream infections with and without septic shock (aHR,
10.96 and 3.71, respectively), transplant failure or rejection (aHR, 1.41), posttransplant laparotomy (aHR, 1.40), prior solidorgan transplant (aHR, 1.48), increasing age (aHR, 1.15/decade), and hepatitis C cirrhosis (aHR, 1.20). The risk of bloodstream
infections and death varied across transplant centers. Median 1-year cumulative hospital costs were higher for patients who developed bloodstream infections within 1 year of transplant compared with patients who were bloodstream infection-free (US
$229 806 vs US $111 313; P < 0.001). Conclusions. Bloodstream infections are common and costly complications after liver
transplantation that are associated with a markedly increased risk of death. The incidence and risk of developing bloodstream infections may vary across transplant centers.

(Transplantation Direct 2016;2: e67; doi: 10.1097/TXD.0000000000000573. Published online 22 February 2016.)

L

iver transplantation has a 1- and 5-year graft survival
rate of 90% and 70%, respectively, that has been enabled by refinements in surgical technique and advances in
immunosuppressive and preventive anti-infective therapy.1
However, bloodstream infections can limit posttransplant
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patient survival by culminating in multiorgan failure, septic
shock, and death.2-5
Recently published single-center studies show that bloodstream infections occur in 17% to 29% of liver transplant recipients6-9 and are associated with an increased risk of death.8,9
Commonly isolated microorganisms were Staphylococcus
aureus, Enterococcus species, Escherichia coli, Klebsiella
pneumoniae, and Pseudomonas aeruginosa, and frequently
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originated from abdominal, pulmonary, and urinary tract
sources.7,8 Patients infected with carbapenem-resistant K. pneumoniae had a particularly high mortality rate.9 Although these
studies increase our understanding of the incidence, microbiology, and outcomes of bloodstream infections after liver transplantation, they are based in single transplant centers that may
have missed bloodstream infections treated in other hospitals.
To determine the epidemiology of bloodstream infections
after liver transplantation, we assembled a large and more
representative cohort of liver transplant recipients from multiple centers using the Healthcare Cost and Utilization Project
State Inpatient Databases (SID). The SID comprise of demographic and billing data that capture inpatient diagnoses and
procedures through International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) coding10
and has been used in the field of liver transplantation to study
perioperative complications of live liver donors,11 delayedonset cytomegalovirus disease,12 and relationships between
hospital/surgeon volume and inpatient mortality.13 The
ICD-9-CM codes used to identify bloodstream infections in
this study have been validated, with a positive predictive
value of 89% and a negative predictive value of 80%.14
Our approach allowed us to follow a large number of patients for a long period, identify bloodstream infections
regardless of whether patients were readmitted to the transplant hospital or a different hospital, and determine hospital
costs. We hypothesized that a significant proportion of bloodstream infections are treated in hospitals other than the original transplant center, and that bloodstream infections are
associated with increased hospital costs and death.

www.transplantationdirect.com

FIGURE 1. Cohort inception of 7912 liver transplant recipients.

solid-organ transplant, and Elixhauser comorbidities were
identified within 1 year before liver transplant and during
the transplant hospitalization.15
Transplant Center Characteristics

We determined the mean annual number of liver transplants
at each transplant center and classified hospitals as either small
(<25 transplants/yr), medium (26 to 75 transplants/yr), or
large (>75 transplants/yr) transplant centers by volume. We
used American Hospital Association Annual Survey data to
determine the number of adult acute-care medical/surgical
beds at each transplant center and identify its teaching status
(presence or absence of residents-in-training).
Bloodstream Infections

We performed a retrospective cohort study of persons
18 years or older who underwent liver transplantation in
nonpediatric hospitals (identified by the American Hospital
Association Annual Hospital Survey) from 2004 to 2010 in
the California SID, 2006 to 2012 in the Florida SID, and
2006 to 2011 in the New York SID (n = 9096). We chose the
cohort inception years to accrue 1 year of preexisting data to
determine comorbidities and at least 1 year of follow-up data.
We excluded persons who lived outside of the state where the
transplant was performed because we would not be able to
track bloodstream infections during readmission in those individuals (n = 1088), and persons who died 2 days or less
posttransplant because they would not have had the opportunity to develop bloodstream infections (n = 96). The final
study population consisted of 7912 liver transplant recipients
(Figure 1). This study was considered exempt by the Washington
University Institutional Review Board.

Bloodstream infections that occurred posttransplant were
identified using ICD-9-CM codes in Table S1 (SDC, http://
links.lww.com/TXD/A21). Bloodstream infections that occurred during the transplant hospitalization were defined as
occurring after transplantation if it was not the primary diagnosis coded for the hospitalization and if 15 days or less
elapsed from day of admission to day of transplant, to minimize the probability of capturing bloodstream infections
occurring before transplant. The time of bloodstream infection was defined as the midpoint between the day of transplant and the day of discharge for bloodstream infections
that occurred during the transplant hospitalization, and the
day of admission for bloodstream infections that were identified on readmission. Bloodstream infections were empirically
categorized as either early-onset (occurring < 100 days posttransplant) or delayed-onset (occurring > 100 days posttransplant) based on the median onset of bloodstream infection,
and as perioperative (occurring < 30 days post-transplant)
or nonperioperative (occurring > 30 days posttransplant).
Possible sources of infection were defined as concurrent coding for intra-abdominal infections, pneumonia, empyema,
and other chest infections, urinary tract infection, endocarditis, and other blood vessel infections, septic arthritis and osteomyelitis, and central nervous system infections. Possible
complications of bloodstream infection were defined as
concurrent coding for acute organ dysfunction and septic
shock.14 The hospitals where bloodstream infections were
identified indicated whether patients were treated at the original transplant center or another hospital.

Patient Characteristics

Death and Other Conditions

Demographic data were determined at the time of liver
transplantation. Possible reasons for liver transplant, prior

Time of inpatient death was determined using the discharge
status variable. Other conditions identified on follow-up were

METHODS
Data Sources

We used the SID from California (2003 to 2011), Florida
(2005 to 2013), and New York (2005 to 2012) because of
the availability of encrypted patient-level identifiers that link
admissions across hospitals over time within a state. The
ICD-9-CM diagnosis and procedure codes used in this study
are listed in Table S1 (SDC, http://links.lww.com/TXD/A21).
Study Design and Patient Population
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newly coded transplant failure or rejection, posttransplant
laparotomy, hemodialysis, and repeat solid-organ transplant
during readmission (Table S1, SDC, http://links.lww.com/
TXD/A21).

TABLE 1.

Demographic and clinical characteristics of liver transplant recipients in the study cohort at the time of organ transplantation
Variables

Hospital Costs

Hospital costs for the transplant hospitalization and any
subsequent readmission 1 year or less after transplantation
were summed to arrive at cumulative 1-year hospital costs
for the study population, after converting hospital charges
to costs using the Healthcare Cost and Utilization Project
cost-to-charge ratio file,16 and adjusting for inflation to
2013 US dollars with the medical care component of the
Consumer Price Index.17 Hospital costs were then compared
between persons who developed bloodstream infection
1 year or less posttransplant and persons who were bloodstream infection-free.
Statistical Analysis

Descriptive statistics were used to describe the demographic and clinical characteristics of the study population.
Kruskall-Wallis testing was performed to determine if cumulative 1-year hospital costs were statistically significantly
higher for persons who developed bloodstream infection
1 year or less posttransplant compared with persons who
were bloodstream infection-free. Spearman rank-order testing was performed to determine if incidence of bloodstream
infections and death across transplant centers was correlated.
Multilevel Cox regression analyses with random intercepts
by transplant center were performed to identify patientlevel and transplant center-level factors associated with
bloodstream infection and death while accounting for shared
frailties in developing bloodstream infection and death in
persons from the same transplant center. Clinically meaningful patient-level and transplant center-level variables that
could be potential risk factors for bloodstream infection
and death were specified and evaluated for proportionality
and time dependency using visual inspection of log-log survival curves and examination of Schoenfeld residuals.18 A series of Cox regression models starting with a hierarchically
well-formulated initial model followed by iterative backward
elimination resulted in a penultimate model that was assessed
for confounding and precision to arrive at the final model.19
Statistical significance was set at a P value of 0.05 or less. All
analyses were performed using SAS Enterprise Guide 5.1
(Cary, NC).
RESULTS
Patient Characteristics

The study population consisted of 7912 adult liver transplant recipients (Table 1). The median age was 56 years;
33% were women, 56% were white, 22% were Hispanic,
74% lived in large metropolitan areas, and 52% had private
insurance. Commonly identified possible reasons for liver
transplant were hepatitis C cirrhosis (44%), hepatocellular
carcinoma (36%), and alcoholic cirrhosis (34%). Two percent of patients had prior solid-organ transplantation. Commonly identified comorbidities were hypertension (49%),
diabetes mellitus (34%), and renal failure (19%). The median duration of follow-up was 4 years (interquartile range,
2.1-5.9 years).

3

Age, y
Mean ± SD
Median (interquartile range)
Female sex (%)
Race (%)
White
Black
Hispanic
Asian or Pacific Islander
Other or missing
Patient location (urban-rural) (%)a
Large metropolitan
Small metropolitan
Micropolitan
Not metropolitan or micropolitan, or missing
Median income of patient ZIP code (%)
First quartile (poorest)
Second quartile
Third quartile
Fourth quartile (wealthiest)
Missing
Expected primary insurance payer (%)
Medicare
Private insurance
Medicaid, self-pay, no charge, other, or missing
Possible reasons for liver transplant, %
Hepatitis C cirrhosis
Hepatocellular carcinoma
Alcoholic cirrhosis
Cirrhosis, no viral etiology identified
Hepatitis B cirrhosis
Nonalcoholic steatohepatitis
Biliary cirrhosis
Prior transplant, %
Liver
Other comorbidities, %
Hypertension
Diabetes mellitus
Renal failure
Depression
Chronic pulmonary disease
Obesity
Drug abuse
Hypothyroidism
Neurologic disorders
Pulmonary circulation disease
Congestive heart failure
Valvular disease
Duration of follow-up, years
Mean
Median (interquartile range)

All recipients, n = 7912
54.38 ± 10.01
56 (50-61)
32.95
56.31
6.95
22.00
8.06
6.67
74.89
20.34
3.37
1.40
20.70
23.10
23.90
23.95
8.34
26.93
51.50
21.56
43.69
36.29
34.11
16.92
9.37
8.34
4.97
2.14
1.86
49.34
33.99
19.40
14.21
12.87
10.62
9.31
9.31
6.96
6.74
6.08
5.46
4.0
4.0 (2.1-5.9)

a
Large metropolitan—at least 1 million residents; small metropolitan—less than 1 million residents;
micropolitan—adjacent to large or small metropolitan area.
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Transplant Center Characteristics

There were 24 hospitals that performed liver transplants
for the study population (Table 2). The mean number of liver
transplants performed by each hospital per year was 49, and
the mean number of acute-care beds was 404. Six hospitals
were small (<25 transplants/year), 12 were medium (26-75
transplants/year), and 6 were large (>75 transplants/year)
transplant centers. Ninety-two percent of transplant centers
were teaching hospitals.
Bloodstream Infections

Bloodstream infections were identified in 29% of liver
transplant recipients, with a range of 19% to 40% across
transplant centers (Figure 2A). Fifty-two percent of bloodstream infections occurred 100 days or less posttransplant
(early-onset), and 48% occurred more than 100 days
posttransplant (delayed-onset) (Table 3). Thirty-four percent
of bloodstream infections occurred 30 days or less posttransplant (perioperative), and 66% occurred more than
30 days posttransplant (nonperioperative). Coding for Gramnegative or anaerobic bacteria, Gram-positive bacteria, multiple microorganisms, and fungus accounted for 23%, 22%,
8%, and 3% bloodstream infections, respectively, whereas
unspecified microorganisms (eg, “bacteremia”) were coded
in 44%. Common possible sources of infection were intraabdominal infections (55%), pneumonia, empyema, and
other chest infections (37%), urinary tract infection (22%),
endocarditis, and other blood vessel infections (7%). Significantly more early-onset bloodstream infections had concurrent coding for intra-abdominal and pulmonary infections
than delayed-onset bloodstream infections (70% vs 40%
and 42% vs 31%, respectively). Acute organ dysfunction,
multiorgan failure, and septic shock were identified in
78%, 54%, and 19% of bloodstream infection hospitalizations, respectively. Renal (64%), cardiovascular (27%),
respiratory (27%), and hematologic (26%) dysfunction commonly occurred. Eighty-one percent of patients with bloodstream infection were diagnosed and treated in the original
transplant center. Although 97% of early-onset bloodstream
infections were identified at the original transplant center,
only 63% of delayed-onset bloodstream infections were
TABLE 2.

Hospital characteristics of liver transplant centers
Variables

All hospitals, n = 24

No. liver transplants performed per year
Mean ± SD
48.96 ± 34.15
Median (range)
43 (2-139)
Transplant center size by mean number of liver transplants performed per year (%)
Small (<25)
6 (25.00)
Medium (26-75)
12 (50.00)
Large (>75)
6 (25.00)
Number of adult acute-care medical/surgical beds
Mean ± SD
403.62 ± 262.20
Median (range)
338 (80-1081)
Transplant center size by bed number
Small (<250)
7 (29.17)
Medium (251 to 500)
10 (41.67)
Large (>500)
7 (29.17)
Teaching hospital (%)
22 (91.67)

FIGURE 2. Incidence of bloodstream infections (A) and inpatient
death (B) stratified according to transplant center. Bubbles signify relative sizes of transplant centers by mean number of liver transplants
per year. Dashed line indicates the mean incidence for the population.

identified at the original transplant center. Thirty-four percent of patients with bloodstream infections died, with a median time to death of 47 days from the bloodstream infection
hospitalization (interquartile range, 15-206 days).
Risk factors for bloodstream infections are in Table 4. In
multivariate analysis, posttransplant laparotomy (hazard ratio [HR], 1.52), increasing age at time of transplantation per
decade (HR, 1.07), female sex (HR, 1.13), prior liver transplant (HR, 1.42), diabetes mellitus (HR, 1.12), renal failure
(HR, 1.27), chronic pulmonary disease (HR, 1.22), and
congestive heart failure (HR, 1.23) were associated with an
increased risk of bloodstream infections. Hepatocellular carcinoma (HR, 0.80) was associated with a decreased risk of
bloodstream infections. Of 24 transplant centers, 4 were significantly more likely than average to have populations that
developed bloodstream infections and 3 were significantly
less likely than average to have populations that developed
bloodstream infections (Figure 3A).
Median 1-year cumulative hospital costs were higher
for patients who developed bloodstream infections within
1 year of transplant compared with patients who were bloodstream infection-free (US $229 806 vs $111 313; P < 0.001)
(Figure 4).
Inpatient Death

Inpatient death was identified in 15% of patients, with a
range of 7% to 25% across transplant centers (Figure 2B).
The incidence of bloodstream infections and death across
transplant centers were strongly correlated (Spearman

Copyright © 2016 The Authors. Transplantation Direct. Published by Wolters Kluwer Health, Inc.
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TABLE 3.

No. patients with bloodstream infections and inpatient death coded during hospitalization in a cohort of 7912 liver transplant
recipients

Bloodstream infections
No. patients (%)
Microorganism
Gram-negative or anaerobic bacteria
Gram-positive bacteria
Multiple organisms
Fungus
No specific microorganism
Possible source of infection
Intra-abdominal infections
Pneumonia, empyema, other chest infections
Urinary tract infection
Endocarditis, other blood vessel infections
Septic arthritis, osteomyelitis
Meningitis, brain abscess, spinal abscess
No identifiable possible source of infection
Acute organ dysfunction
Renal
Cardiovascular
Respiratory
Hematologic
Metabolic
Hepatic
Neurologic
Multiorgan failure (>2 acute organ dysfunction)
Septic shock
Admitted to the original liver transplant center
Died
Median time to death in days after admission with bloodstream
infection (interquartile range)
Inpatient death
No. patients (%)
Bloodstream infection
Transplant failure or rejection
Dialysis

All

Early (<100 d posttransplant)

Delayed (>100 d posttransplant)

2326 (29.40)

1212 (52.11)

1114 (47.89)

524 (22.53)
518 (22.27)
192 (8.25)
62 (2.67)
1030 (44.28)

251 (20.71)
281 (23.18)
131 (10.81)
38 (3.14)
511 (42.16)

273 (24.51)
237 (21.27)
61 (5.48)
24 (2.15)
519 (46.59)

1290 (55.46)
858 (36.89)
506 (21.75)
165 (7.09)
20 (0.86)
11 (0.47)
436 (18.74)

847 (69.88)
510 (42.08)
250 (20.63)
73 (6.02)
*
*
160 (13.20)

443 (39.77)
348 (31.24)
256 (22.98)
92 (8.26)
*
*
276 (24.78)

1479 (63.59)
632 (27.17)
622 (26.74)
614 (26.40)
427 (18.36)
416 (17.88)
262 (11.26)
1256 (54.00)
453 (19.48)
1877 (80.70)
802 (34.48)
47 (15-206)

786 (64.85)
352 (29.04)
369 (30.45)
384 (31.68)
217 (17.90)
297 (24.50)
138 (11.39)
730 (60.23)
252 (20.79)
1174 (96.86)
412 (33.99)
44 (16-227)

693 (62.21)
280 (25.13)
253 (22.71)
230 (20.65)
210 (18.85)
119 (10.68)
124 (11.13)
526 (47.22)
201 (18.04)
703 (63.11)
390 (35.01)
51 (15-176)

1180 (14.91)
756 (64.07)
628 (53.22)
497 (42.12)

380 (32.20)
264 (69.47)
174 (45.79)
204 (53.68)

800 (67.80)
492 (61.50)
454 (56.75)
293 (36.63)

a

AHRQ-HCUP prohibits reporting cell sizes <11 in number.
AHRQ-HCUP, Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project

correlation coefficient, 0.66; P < 0.001). Thirty-two percent of deaths occurred 100 days or less posttransplant, and
68% occurred more than 100 days posttransplant (Table 3).
Common conditions during the death hospitalization were
bloodstream infections (64%), transplant failure or rejection
(53%), and hemodialysis (42%).
Risk factors for death are in Table 5. In multivariate analysis, bloodstream infections without septic shock (HR, 3.71),
bloodstream infections with septic shock (HR, 10.96), transplant failure or rejection (HR, 1.41), posttransplant laparotomy (HR, 1.40), increasing age at time of transplantation per
decade (HR, 1.15), hepatitis C cirrhosis (HR, 1.20), and prior
solid-organ transplant (HR, 1.48) were associated with an increased risk of death. Of 24 transplant centers, 4 were significantly more likely than average to have populations that died
and 2 were significantly less likely than average to have populations that died (Figure 3B). Bloodstream infections with or
without septic shock (HR, 4.8), early-onset bloodstream

infections (HR, 5.3), and delayed-onset bloodstream infections (HR, 4.3) were associated with increased risk of death
after adjusting for the same covariates.
DISCUSSION
We found that bloodstream infections were common and
costly complications after liver transplantation that were associated with a nearly 5-fold increased risk of death. These
results identify bloodstream infections as significant impediments to successful liver transplantation across multiple
transplant centers and highlight the need for more clinical
and translational research into how bloodstream infections
in these vulnerable hosts can be better prevented and treated.
Interestingly, almost half of first episodes of bloodstream infection were identified more than 100 days posttransplant, of
which nearly 40% were treated at a hospital other than the
original transplant center. This finding underscores the ability

Copyright © 2016 The Authors. Transplantation Direct. Published by Wolters Kluwer Health, Inc.
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TABLE 4.

Cox proportional hazard model of risk factors for bloodstream infections
Univariate analysis
Risk factor
Patient-level variables
Previous exploratory laparotomy
Increasing age at time of transplantation per decade
Female sex
Possible reasons for liver transplant
Hepatitis C cirrhosis
Hepatocellular carcinoma
Alcoholic cirrhosis
Cirrhosis, no viral etiology identified
Hepatitis B cirrhosis
Non-alcoholic steatohepatitis
Biliary cirrhosis
Prior liver transplant
Other comorbidities
Diabetes mellitus
Renal failure
Chronic pulmonary disease
Obese
Congestive heart failure
Transplant center-level variables
Transplant center size by volume
Small (<25 transplants/y)
Medium (26 to 75 transplants/y)
Large (>75 transplants/y)
Transplant center size by bed number
Small (<250)
Medium (251-500)
Large (>500)
Teaching hospital

Multivariate analysis

HR (95% CI)

P

HR (95% CI)

P

1.59 (1.43-1.77)
1.04 (1.00-1.09)
1.20 (1.10-1.30)

<0.001
0.053
<0.001

1.52 (1.36-1.70)
1.07 (1.02-1.11)
1.13 (1.04-1.24)

<0.001
0.004
0.004

1.00 (0.92-1.08)
0.76 (0.70-0.83)
1.05 (0.97-1.14)
1.10 (0.99-1.22)
0.84 (0.73-0.98)
1.15 (1.00-1.32)
1.02 (0.85-1.23)
1.67 (1.31-2.13)

1.000
<0.001
0.249
0.089
0.022
0.048
0.797
<0.001

0.80 (0.73-0.88)

<0.001

1.42 (1.10-1.82)

0.006

1.14 (1.04-1.24)
1.44 (1.31-1.59)
1.30 (1.16-1.46)
1.18 (1.04-1.34)
1.47 (1.27-1.71)

0.003
<0.001
<0.001
0.010
<0.001

1.12 (1.02-1.22)
1.27 (1.15-1.41)
1.22 (1.08-1.36)

0.015
<0.001
0.001

1.23 (1.06-1.43)

0.008

1.00
1.10 (0.92-1.32)
1.00 (0.84-1.19)

0.275
0.988

1.00
0.87 (0.79-0.96)
0.90 (0.82-1.00)
1.07 (0.83-1.38)

0.006
0.047
0.587

of our analysis to identify bloodstream infections over a long
period, and regardless of whether patients were readmitted
to the transplant center or another hospital. Delayed-onset
bloodstream infections were less commonly concurrently
coded with intra-abdominal infections than were early-onset
infections, likely reflecting a shift away from the surgical site
as an obvious source of infection as time elapses after transplant.7,8 In contrast, urinary tract, endovascular, bone and
joint, and central nervous system infections were more commonly concurrently coded with delayed-onset bloodstream
infections than early-onset bloodstream infections. Acute
organ dysfunction, multiorgan failure, and septic shock occurred commonly in hospitalizations wherein bloodstream
infections were identified, and possibly reflect significant morbidity caused by bloodstream infections.7,20,21
Posttransplant laparotomy and prior liver transplant were
the strongest risk factors for bloodstream infections in our
analysis. Return to surgery and prior liver transplant have
previously been shown to be associated with bloodstream infections in single-center studies.8,20,22 Return to surgery is
typically performed for technical complications that arise
posttransplant, and include biliary leak or stricture, portal
vein or hepatic artery thrombosis, hemorrhage and infarction.23,24 Disrupted anatomy coupled with critical illness,
complex surgery, and prolonged hospitalization may predispose patients to develop intra-abdominal, pulmonary,

urinary tract, and vascular catheter infections that culminate
in bloodstream infections. Repeat liver transplantation has
higher rates of allograft failure compared with primary liver
transplantation,25,26 which can result in an increased risk of
bloodstream infections. Other risk factors were increasing
age, diabetes mellitus, renal failure, chronic pulmonary disease, and congestive heart failure, which indicate that comorbidities can contribute to increasing the risk of bloodstream
infections among liver transplant recipients. Hepatocellular
carcinoma was associated with a decreased risk of bloodstream infections, likely because patients who underwent
transplantation for early-stage hepatocellular carcinoma as defined by the Milan criteria27-29 had lower model for end-stage
liver disease (MELD) scores than patients who underwent
transplantation for end-stage liver disease.30,31 Single-center
studies indicate that higher MELD scores are associated with
increased bloodstream infection risk.8,20
We found variability in the shared susceptibilities of liver
transplant recipients clustered within transplant centers in developing bloodstream infections, after accounting for patientlevel factors that included posttransplant laparotomy, prior
liver transplant, age, sex, and several comorbidities. The most
likely reason for variability is residual confounding given our
inability to capture all patient-level factors that can be associated with bloodstream infections. Some transplant centers
operate on sicker and more complicated patients than others,

Copyright © 2016 The Authors. Transplantation Direct. Published by Wolters Kluwer Health, Inc.
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FIGURE 3. Transplant center-level effects for bloodstream infection
(A) and death (B). Blue circles represent point estimates, and red bars
indicate 95% confidence intervals. Dashed line indicates the average
risk for the population.

which can result in more morbid cohorts who are at greater
risk of bloodstream infections and death than average. Other
possible reasons for variability include shared antibiotic resistance patterns for bacteria among patients transplanted
in the same transplant center,9,20-22,32-34 shared infection
control policies,8,35 and shared surgical teams.23,24 Patients
transplanted in hospitals with high rates of multidrugresistant bacteria, such as methicillin-resistant S. aureus, extended spectrum β lactamase-producing P. aeruginosa and
carbapenem-resistant K. pneumoniae may be at increased
risk of developing bloodstream infections given the reduced
efficacy of first-line antibiotics in treating sources of infection.9,21 Aggressive infection control policies that have been
shown to reduce the transmission of methicillin-resistant S.
aureus among liver transplant recipients (active surveillance,
contact isolation and decolonization) may be more effectively
implemented in some transplant centers than others.8,35 Surgical teams in different transplant centers may have varying
levels of technical proficiency, which can lead to different biliary and vascular complication rates23,24 and different risks
of bloodstream infection. Variability in bloodstream infection risk across transplant centers should be confirmed with
more granular clinical data.
We found that bloodstream infections, multiorgan failure,
and septic shock were strongly associated with death, supporting recently published single-center studies.8,9 Some bloodstream infections can initiate a rapidly vicious circle of
cytokine-driven hyperinflammation, septic shock, and death
within a few days of onset,9,36 whereas others can result in
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protracted hospitalization, persistent organ dysfunction, immune exhaustion, and frailty followed by death after several
weeks or months.37 Alternatively, bloodstream infections
may be markers for more direct determinants of death, such
as posttransplant technical complications or acute allograft rejection. Although we adjusted for posttransplant laparotomy
and transplant failure or rejection in our Cox regression
models, residual confounding may have been present. The precise role of bloodstream infections in the causal pathway to
death cannot be determined in this retrospective populationlevel epidemiologic study.
The strengths of our study are the large size of the study
population, long duration of follow-up, and identification
of bloodstream infections regardless of admission to the
transplant center or another hospital. It however has some
limitations. Comorbidities and clinical events were identified
using ICD-9-CM codes which are not perfectly accurate.38
However, the ICD-9-CM codes used to identify bloodstream
infections in this study have been validated and found to have
reasonable accuracy.14 Moreover, misclassification stemming from occasionally inaccurate ICD-9-CM coding will result in more conservative estimates of associations between
bloodstream infections and death, or bloodstream infections
and potential risk factors, thereby maintaining the validity
of our results. The data source used in this study contains
only demographic and inpatient hospital ICD-9-CM billing
data occurring within a state and does not have microbiology
information, laboratory test results, MELD scores, medications prescribed, or information regarding the presence of

FIGURE 4. Natural log of cumulative 1-year hospital costs stratified
according absence (A) or presence (B) of bloodstream infection
within 1 year posttransplant.
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TABLE 5.

Cox proportional hazard model of risk factors for inpatient death
Univariate analysis
Risk factor
Patient-level variables
Bloodstream infections
Microorganism
Gram-negative or anaerobic bacteria
Gram-positive bacteria
Multiple organisms
Fungus
No specific microorganism
Without multiorgan failure
With multiorgan failure
Early-onset (<100 days posttransplant)
Delayed-onset (>100 days posttransplant)
Without septic shock
With septic shock
Transplant failure or rejection
Posttransplant laparotomy
Increasing age at time of transplantation per decade
Female sex
Possible reasons for liver transplant
Hepatitis C cirrhosis
Hepatocellular carcinoma
Alcoholic cirrhosis
Cirrhosis, no viral etiology identified
Hepatitis B cirrhosis
Nonalcoholic steatohepatitis
Biliary cirrhosis
Prior solid-organ transplant
Other comorbidities
Diabetes mellitus
Renal failure
Chronic pulmonary disease
Obese
Congestive heart failure
Transplant center-level variables
Transplant center size by volume
Small (<25 transplants/y)
Medium (26 to 75 transplants/y)
Large (>75 transplants/y)
Transplant center size by bed number
Small (<250)
Medium (251-500)
Large (>500)
Teaching hospital

Multivariate analysis

HR (95% CI)

P

5.73 (5.07-6.48)

<0.001

5.34 (4.46-6.40)
4.73 (3.93-5.70)
7.58 (5.97-9.62)
5.40 (3.44-8.46)
6.17 (5.35-7.12)
2.96 (2.50-3.50)
8.70 (7.64-9.90)
6.19 (5.38-7.12)
5.32 (4.62 – 6.12)
4.44 (3.89-5.06)
12.98 (11.11-15.16)
2.31 (2.03-2.62)
2.20 (1.93-2.51)
1.12 (1.05-1.19)
1.19 (1.05-1.34)

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.005

1.26 (1.12-1.41)
1.00 (0.89-1.13)
1.02 (0.91-1.16)
0.90 (0.77-1.06)
0.94 (0.77-1.15)
0.97 (0.79-1.20)
0.76 (0.56-1.02)
1.93 (1.44-2.59)

<0.001
1.000
0.684
0.194
0.570
0.808
0.065
<0.001

1.13 (1.00-1.27)
1.29 (1.12-1.48)
1.24 (1.06-1.45)
0.98 (0.81-1.18)
1.55 (1.26-1.89)

0.044
<0.001
0.001
0.815
<0.001

1.00
1.26 (1.05-1.51)
1.08 (0.90-1.29)

0.012
0.423

1.00
0.92 (0.83-1.01)
1.08 (0.98-1.20)
1.33 (1.03-1.72)

0.081
0.121
0.029

central venous catheters. We therefore could not precisely
identify causative microorganisms, antibiotic susceptibilities,
antimicrobials administered, or whether bloodstream infections were catheter-related. Although classes of microorganisms were identified in the majority of cases, a significant
proportion of microorganisms were unspecified (eg, “bacteremia”). However, Cox regression analyses showed that
unspecified microorganisms were similarly associated with
death as specific microorganisms, indicating comparably
morbid conditions. Despite its limitations, our study provides population-level information regarding the epidemiology of bloodstream infections after liver transplantation

HR (95% CI)

P

3.71 (3.23-4.26)
10.96 (9.31-12.90)
1.41 (1.23-1.61)
1.40 (1.22-1.61)
1.15 (1.06-1.35)

<0.001
<0.001
<0.001
<0.001
<0.001

1.20 (1.06-1.35)

0.003

1.48 (1.10-1.99)

0.011

in the current era, identifies variability in the incidence and
risk of developing bloodstream infections and death across
transplant centers after accounting for many patient-level
factors, and highlights the need for further research regarding better prevention and management strategies for bloodstream infections across transplant centers nationally.
In summary, we showed that bloodstream infections after
liver transplantation were common and costly complications
that were associated with a markedly increased risk of death.
The incidence and risk of developing bloodstream infections
may vary across transplant centers. Better prevention and
management strategies should be subjects of future research.
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